ArticleScientific reports2018
A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Detection ofBiomolecules · 2021Trial
- Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2- Advanced Breast Cancer.Drugs · 2026Review
- Understanding the transfer and persistence of antimicrobial resistance in aquaculture using a model teleost gut system.Animal microbiome · 2025Article
- Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review.The journal of liquid biopsy · 2024Review
- [Sperm Mosaic Variants and Their Influence on the Offspring].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Phosphoramidate Azole Oligonucleotides for Single Nucleotide Polymorphism Detection by PCR.International journal of molecular sciences · 2024Article
- Identification of breast cancer-associated PIK3CA H1047R mutation in blood circulation using an asymmetric PCR assay.PloS one · 2024Article
- An ultra-sensitive and rapid immunosensor for the onsite detection of circulating tumor DNA in breast cancer.Frontiers in bioengineering and biotechnology · 2024Article
- Identification of DNA variants at ultra-low variant allele frequencies via Taq polymerase cleavage of wild-specific blockers.Analytical and bioanalytical chemistry · 2023Article
- Allele-Specific PCR for PIK3CA Mutation Detection Using Phosphoryl Guanidine Modified Primers.Diagnostics (Basel, Switzerland) · 2023Article
- Nuclease Enrichment and qPCR Detection of Rare Nucleotide Variants.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Real-Time Polymerase Chain Reaction: Current Techniques, Applications, and Role in COVID-19 Diagnosis.Genes · 2022Review
- Article
- Development of a multiplex allele-specific qPCR approach for testing PIK3CA mutations in patients with colorectal cancer.Heliyon · 2022Article
- Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology.Biophysics reviews · 2022Review
- Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy.Exploration of targeted anti-tumor therapy · 2022Review
- A Sensitive PCR-Based Method for Somatic Mutations Enrichment and Screening.Cancer management and research · 2021Article
- Review
- Integrating Quantitative Assays with Biologically Based Mathematical Modeling for Predictive Oncology.iScience · 2020Review
- PIK3CA mutation enrichment and quantitation from blood and tissue.Scientific reports · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
PIK3CA mutations are seemingly the most common driver mutations in breast cancer with H1047R and E545K being the most common of these, accounting together for around 60% of all PIK3CA mutations and have promising therapeutic implications. Given the low sensitivity and the high cost of current genotyping methods we sought to develop fast, simple and inexpensive assays for PIK3CA H1047R and E545K mutation screening in clinical material. The methods we describe are based on a real-time PCR including a mutation specific primer combined with a non-productive oligonucleotide which inhibits wild-type amplification and a parallel internal control reaction. We demonstrate consistent detection of PIK3CA H1047R mutant DNA in genomic DNA extracted from frozen breast cancer biopsies, FFPE material or cancer cell lines with a detection sensitivity of approximately 5% mutant allele fraction and validate these results using both Sanger sequencing and deep next generation sequencing methods. The detection sensitivity for PIK3CA E545K mutation was approximately 10%. We propose these methods as simple, fast and inexpensive diagnostic tools to determine PIK3CA mutation status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.